CN Patent

CN1606545A — 作为nk1拮抗剂的吡咯烷和哌啶衍生物

Assigned to Merck Sharp and Dohme LLC · Expires 2005-04-13 · 21y expired

What this patent protects

具有式(I)的NK 1 拮抗剂，其中Ar 1 和Ar 2 是任选取代的苯基或杂芳基，Ar 2 R 4 R 5 X 1 X 1 是醚、硫或亚氨键，R 4 和R 5 不都是H或烷基，和剩下的变量如说明书所定义，可用于治疗许多疾病，包含呕吐、忧郁症、焦虑和咳嗽。药物组合物。治疗方法和与其它药剂的联用。

USPTO Abstract

具有式(I)的NK 1 拮抗剂，其中Ar 1 和Ar 2 是任选取代的苯基或杂芳基，Ar 2 R 4 R 5 X 1 X 1 是醚、硫或亚氨键，R 4 和R 5 不都是H或烷基，和剩下的变量如说明书所定义，可用于治疗许多疾病，包含呕吐、忧郁症、焦虑和咳嗽。药物组合物。治疗方法和与其它药剂的联用。

Drugs covered by this patent

Patent Metadata

Patent number
CN1606545A
Jurisdiction
CN
Classification
—
Expires
2005-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.